Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myeloid, Acute 1

Interventions

venetoclax 7Azacitidine 5Specimen Handling 4fludarabine phosphate 3Tacrolimus 2Mitoxantrone 2Melphalan 2Cyclophosphamide 2Biopsy 2vactosertib 1regorafenib 1methyl cis-3,4-diamino-2,3,4,6-tetradeoxy-alpha-L-lyxo-hexopyranoside Pt(II) 1iadademstat 1gilteritinib 1fludarabine 1decitabine and cedazuridine drug combination 1beta-apocarotenoid-14',13'-dioxygenase 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1aldesleukin 1TAK-243 1Stem Cell Transplantation 1Radiotherapy, Intensity-Modulated 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Interleukin-2 1Idarubicin 1IL32 protein, human 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Leukemia, Myeloid, Acute × iadademstat × Clear all
NCT06514261 2026-05-13

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

National Cancer Institute (NCI)

Phase 1 Suspended
45 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡